A Study Evaluating the Safety, Tolerability and Preliminary Efficacy of IBI322 in Subjects With Hematologic Malignancy

NCT04795128 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

70

Enrollment

INDUSTRY

Sponsor class

Conditions

Hematologic Malignancy

Interventions

BIOLOGICAL: IBI322

Sponsor

Innovent Biologics (Suzhou) Co. Ltd.